Claims
- 1. A method of determining the ability of a test compound to affect the activity of ABC1 protein, said method comprising the steps of:
a) providing ABC1-expressing cells; b) contacting said ABC1-expressing cells with a composition containing said test compound; and c) measuring ABC1 biological activity of said cells contacted with said test compound.
- 2. The method of claim 1, further comprising:
d) comparing said ABC1 biological activity of said cells contacted with said test compound to ABC1 biological activity of ABC1-expressing cells not contacted with a test compound, wherein altered ABC1 biological activity of said cells contacted with said test compound indicates that said test compound affects the activity of ABC1 protein.
- 3. The method of claim 2, wherein labeled substrate of ABC1 protein has been introduced into said ABC1-expressing cells.
- 4. The method of claim 3, wherein ABC1 biological activity is measured by determining the level of efflux of said substrate from said ABC1-expressing cells, wherein a difference in the efflux of said substrate from said cells contacted with said test compound, relative to the level of efflux of substrate from said cells not contacted with a test compound, indicates that said test compound affects the activity of ABC1 protein.
- 5. The method of claim 4, wherein efflux of said substrate is determined by measuring the ability of cells to transfer substrate to an extracellular acceptor of said substrate.
- 6. A method of determining the ability of a test compound to affect the activity of ABC1 protein, said method comprising the steps of:
a) introducing labeled substrate into ABC1-expressing cells; b) adding a test composition comprising said test compound to a first portion of said cells, and adding a control composition to a second portion of said cells, wherein said control composition is essentially identical to said test composition except that said control composition does not include said test compound; c) measuring the level of efflux of substrate from each portion of said cells by separately combining said first and said second portions of said cells with an efflux media, said efflux media comprising an ABC1 acceptor, and measuring the amount of substrate that associates with said ABC1 acceptor in each of said portions of said cells; and d) comparing the level of efflux of substrate from said first portion of said cells to the level of efflux of substrate from said second portion of said cells, wherein a change in the level of efflux indicates that said test compound affects the activity of the ABC1 protein.
- 7. The method of claim 5 or 6, wherein said substrate is cholesterol or a phospholipid.
- 8. The method of claim 5 or 6, wherein said ABC1-expressing cells are fibroblasts or macrophages.
- 9. The method of claim 5 or 6, wherein said substrate is labeled with tritium, a radioactive label, a fluorescent label or a luminescent label.
- 10. The method of claim 5 or 6, wherein said acceptor is ApoAI or HDL3.
- 11. The method of claim 5 or 6, wherein the amount of substrate that associates with an acceptor is measured by determining the amount of labeled substrate in the culture medium.
- 12. The method of claim 5 or 6, wherein the substrate is cholesterol and cholesterol efflux is determined as the percentage of total cholesterol in the culture medium after various times of incubation.
- 13. The method of claim 5 or 6, wherein a multi-well format is used.
- 14. The method of claim 13, wherein the multi-well format is a 96-well format.
- 15. The method of claim 14, wherein the 96-well format comprises a positive control.
- 16. The method of claim 15, wherein the positive control comprises adding an ABC1 agonist to at least one well containing said ABC-1 expressing cells and measuring ABC1 biological activity of said cells contacted with said test compound.
- 17. The method of claim 16, wherein said agonist is cAMP, a cAMP analog, cpt-cAMP, vanadate, protein kinase A, protein kinase C, IBMX1, okadaic acid, a prostaglandin, an oxysterol or a PDE inhibitor.
- 18. The method of claim 14, wherein the 96-well format comprises a negative control.
- 19. The method of claim 18, wherein the negative control comprises adding an ABC1 antagonist to at least one well containing said ABC1-expressing cells and measuring ABC1 biological activity of said cells contacted with said test compound.
- 20. The method of claim 19, wherein said antagonist is glibenclamide, glyburide, sulfobromophthalein, flufenamic acid, diphenylamine-2-carbonic acid, DIDS, bumetanide or furosemide.
- 21. The method of claim 20, wherein the 96-well format further comprises a positive control.
- 22. The method of claim 21, wherein the positive control comprises adding an ABC1 agonist to at least one well containing said ABC1-expressing cells and measuring ABC1 biological activity of said cells contacted with said test compound.
- 23. The method of claim 17, wherein said agonist is cAMP, a cAMP analog, cpt-cAMP, vanadate, protein kinase A, protein kinase C, IBMX1, okadaic acid, a prostaglandin, an oxysterol or a PDE inhibitor.
- 24. The method of claim 2, wherein labeled anions have been introduced into said ABC1-expressing cells.
- 25. The method of claim 24, wherein ABC1 biological activity is measured by determining the level of efflux of said anions from said ABC1-expressing cells, wherein a difference in the efflux of said anions from said cells contacted with said test compound, relative to the level of efflux of anions in said cells not contacted with a test compound, indicates that said test compound affects the activity of ABC1 protein.
- 26. The method of claim 25, wherein efflux of said anions is determined by measuring the ability of cells to transfer anions to the extracellular medium.
- 27. A method of determining the ability of a test compound to affect the activity of ABC1 protein, said method comprising the steps of:
a) introducing labeled anions into ABC1-expressing cells; b) adding a test composition comprising said test compound to a first portion of said cells, and adding a control composition to a second portion of said cells, wherein said control composition is essentially identical to said test composition except that said control composition does not include said test compound; and c) comparing the level of efflux of anions from said first portion of said cells to the level of efflux of anions from said second portion of said cells, wherein a change in the level of efflux indicates that said test compound affects the activity of the ABC1 protein.
- 28. A method of determining the ability of a test compound to affect the expression of ABC1 protein, said method comprising the steps of:
a) providing ABC1-expressing cells; b) contacting said ABC1-expressing cells with a test compound; and c) measuring ABC1 protein expression of said cells contacted with said test compound.
- 29. The method of claim 28, further comprising:
d) comparing the amount of ABC1 protein from said ABC1-expressing cells to the amount of ABC1 protein from ABC1-expressing cells not contacted with a test compound, wherein a change in the amount of ABC1 protein indicates that said test compound affects the expression of the ABC1 protein.
- 30. The method of claim 29, wherein a multi-well format is used.
- 31. A method of determining the ability of a test compound to affect the expression of ABC1 protein, said method comprising the steps of:
a) adding a test composition comprising said test compound to a first portion of ABC1-expressing cells, and adding a control composition to a second portion of said cells, wherein said control composition is essentially identical to said test composition except that said control composition does not include said test compound; and b) comparing the amount of ABC1 protein from said first portion of said cells to the amount of ABC1 protein from said second portion of said cells, wherein a change in the amount of ABC1 protein indicates that said test compound affects the expression of the ABC1 protein.
- 32. A method of determining the ability of a test compound to affect the transcription of ABC1 mRNA, said method comprising the steps of:
a) providing ABC1-expressing cells; b) contacting said ABC1-expressing cells with said test compound; and c) measuring comparing the amount of ABC1 mRNA from said ABC1-expressing ABC1 mRNA of said cells contacted with said test compound.
- 33. The method of claim 32, further comprising:
d) comparing the amount of ABC1 mRNA from said ABC1-expressing cells to the amount of ABC1 mRNA from ABC1-expressing cells not contacted with a test compound, wherein a change in the amount of ABC1 mRNA indicates that said test compound affects the transcription of ABC1 mRNA.
- 34. The method of claim 33, wherein a multi-well format is used.
- 35. A method of determining the ability of a test compound to affect the transcription of ABC1 mRNA, said method comprising the steps of:
a) adding a test composition comprising said test compound to a first portion of ABC1-expressing cells, and adding a control composition to a second portion of said cells, wherein said control composition is essentially identical to said test composition except that said control composition does not include said test compound; and b) comparing the amount of ABC1 mRNA from said first portion of said cells to the amount of ABC1 mRNA from said second portion of said cells, wherein a change in the amount of ABC1 mRNA indicates that said test compound affects the transcription of ABC1 mRNA.
- 36. A method of treating a human having low HDL cholesterol or a cardiovascular disease, said method comprising administering to said human a nucleic acid molecule encoding an ABC1 polypeptide or a cholesterol-regulating fragment thereof.
- 37. The method of claim 36, wherein said ABC1 polypeptide has the amino acid sequence of SEQ ID NO: 1.
- 38. The method of claim 37, wherein said ABC1 polypeptide comprises a mutation that increases the stability of said ABC1 polypeptide.
- 39. The method of claim 37, wherein said ABC1 polypeptide comprises a mutation that increases the biological activity of said ABC1 polypeptide.
- 40. The method of claim 39, wherein said biological activity is the transport of cholesterol or phospholipid.
- 41. The method of claim 36, wherein said human has a lower than normal HDL-cholesterol level.
- 42. A method of increasing ABC1 biological activity in a human, said method comprising administering to said human a nucleic acid molecule that encodes a polypeptide having ABC1 biological activity.
- 43. The method of claim 42, wherein said nucleic acid molecule hybridizes under high stringency conditions to the nucleotide sequence of SEQ ID NO:2.
- 44. The method of claim 42, wherein said human has a disease selected from the group consisting of Alzheimer's disease, Niemann-Pick disease, Huntington's disease, x-linked adrenoleukodystrophy disease and cancer.
- 45. The method of claim 44, wherein said human has a disease selected from the group consisting of cardiovascular disease, coronary artery disease, cerebrovascular disease, coronary restenosis, or peripheral vascular disease.
- 46. A method of preventing cardiovascular disease in a human, said method comprising administering to said human a nucleic acid operably linked to a promoter wherein said nucleic acid encodes an ABC1 polypeptide.
- 47. A method of preventing or ameliorating the effects of an ABC1 related disease in a human, said method comprising introducing into said human a nucleic acid molecule operably linked to an ABC1 promoter, wherein said nucleic acid encodes an ABC1 polypeptide that has ABC1 biological activity.
- 48. The method of claims 36, 42, 46 or 47, wherein said nucleic acid molecule is provided in a delivery system selected from among a baculovirus, herpes virus, adenovirus, adeno-associated virus, bacterial cell, eukaryotic cell, naked DNA and DNA-liposome complex.
Parent Case Info
[0001] This application is a continuation of and claims priority of Ser. No. 10/617,334, filed 10 Jul. 2003, and Ser. No. 10/452,510, filed 2 Jun. 2003, both of which are continuing applications of Ser. No. 09/526,193, filed 15 Mar. 2000, now U.S. Pat. No. 6,617,122, which claims priority from U.S. Provisional Application No. 60/124,702, filed Mar. 15, 1999, U.S. Provisional Application No. 60/138,048, filed Jun. 8, 1999, U.S. Provisional Application No. 60/139,600, filed Jun. 17, 1999, and U.S. Provisional Application No. 60/151,977, filed Sep. 1, 1999, the disclosures of all of which are hereby incorporated by reference in their entirety.
Provisional Applications (4)
|
Number |
Date |
Country |
|
60124702 |
Mar 1999 |
US |
|
60138048 |
Jun 1999 |
US |
|
60139600 |
Jun 1999 |
US |
|
60151977 |
Sep 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
| Parent |
09526193 |
Mar 2000 |
US |
| Child |
10452510 |
Jun 2003 |
US |
Continuations (3)
|
Number |
Date |
Country |
| Parent |
10617334 |
Jul 2003 |
US |
| Child |
10833679 |
Apr 2004 |
US |
| Parent |
10452510 |
Jun 2003 |
US |
| Child |
10833679 |
Apr 2004 |
US |
| Parent |
09526193 |
Mar 2000 |
US |
| Child |
10617334 |
|
US |